QDEL - QuidelOrtho Corporation
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 ended September 27, 2026, shortly after the market closes at 4:00 p.m. ET on Tuesday, November 3, 2026.
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Elutia (NASDAQ: ELUT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Profitability This table compares QuidelOrtho and Elutia's net margins,
SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to each employee's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings more than 20 years of experience across investor relations, corporate strategy and equity research at global organizations.
Cooper Companies (NASDAQ: COO - Get Free Report) and QuidelOrtho (NASDAQ: QDEL - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Profitability This table compares Cooper Companies and QuidelOrtho's net
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
Squarepoint Ops LLC acquired a new position in QuidelOrtho Corporation (NASDAQ: QDEL) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 85,251 shares of the company's stock, valued at approximately $1,493,000. Squarepoint Ops LLC owned 0.12% of QuidelOrtho as of
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
QuidelOrtho Corporation (NASDAQ: QDEL - Get Free Report)'s share price gapped down before the market opened on Friday. The stock had previously closed at $16.32, but opened at $12.67. QuidelOrtho shares last traded at $11.9830, with a volume of 631,070 shares trading hands. Key Stories Impacting QuidelOrtho Here are the key news stories impacting QuidelOrtho
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.
QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago.
― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency.
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.